**Core tip:** Myopericarditis symptoms can be variable but generally presents with ischaemic sounding chest pain or pleuritic chest pain and cardiac biomarker elevation (troponin I and T). Non-typhoidal salmonella (NTS) generally presents as a non-bloody infectious diarrhoea. *Salmonella enterica* has multiple subtypes, with *Salmonella typhi* and *paratyphi* causing typhoid fever. However, there are a large number of NTS, which may include *Salmonella choleraesuis, enteritidis*, and *typhimurium*. Relevant investigations may consist of laboratory blood tests, electrocardiogram, echocardiography, coronary angiography, cardiac magnetic resonance imaging, cardiac biopsy, and faecal culture for *Salmonella*. *Salmonella* is a rare cause of myopericarditis; however, it should be considered when patients with symptoms of myocarditis or pericarditis present with a history of diarrhoea, abdominal pain and fever.

INTRODUCTION
============

Myocarditis is defined as an inflammatory disorder of the myocardium, formally diagnosed on clinical biopsy, however many cases are often diagnosed clinically\[[@B1]\]. Pericarditis, also inflammatory, is when the inflammation primarily involves the pericardial sac. Given their close anatomical relation, co-inflammation can occur as part of a syndrome known as myopericarditis, however, clinical manifestations are predominantly myocarditic or pericarditic\[[@B2]\]. The aetiology of myopericarditis is varied, ranging from infections (viral being the most common), autoinflammatory conditions, neoplasms, trauma, metabolic and idiopathic\[[@B3]\]. A rare, but potentially serious cause is as a sequelae of Salmonella infection.

Most cases of *Salmonella* myocarditis are associated with typhoid fever (*Salmonella typhi/paratyphi*), complicating up to 5% of all infections, and is well described in literature\[[@B4]\]. We conducted a systematic review of all case studies and case series published on nontyphoidal salmonella (NTS) associated pericarditis and/or myocarditis from January 1970 to March 2019. Both authors (Jin D and Kao CY) searched on PubMed and EMBASE using the search terms "Salmonella AND myocarditis" and "Salmonella AND pericarditis". PubMed was further searched for the combined MeSH values of "Myocarditis" as well as "Salmonella (excluding typhi and paratyphi)". Paediatric and non-human cases were excluded. References of articles were then further reviewed. We aim to discuss a case NTS myopericarditis, as well as reviewing the relevant literature.

CASE PRESENTATION
=================

Chief complaints
----------------

We report a case of a 39-year old male, with no previous medical history, presenting with *Salmonella typhimurium* myopericarditis.

Personal and family history
---------------------------

The patient initially presented to our emergency department (ED) with acute chest discomfort, on the background of a four-day history of persistent, watery diarrhoea, occurring three to four times per day. On Day 0 (four days prior to admission), he noticed diffused abdominal cramps, bloating, nausea without vomiting, and fever. There was no history of recent travel, however he had a seven-year-old daughter, who had a one-week history of the same symptoms which had resolved prior to the patient's presentation. There was no report of blood in the diarrhoea, which was beginning to decrease and form solid motions by Day 4.

However, it was during this stage (Day 4) that the patient noted central chest discomfort, described as a burning sensation, radiating to the axilla and neck, associated with diaphoresis and self-resolving shortness of breath. This was not exacerbated by exercise, however there was some relief with leaning forwards. He initially presented to his General Practitioner (GP), who organised for faecal cultures, before referring onto ED.

Laboratory examinations
-----------------------

At presentation to ED, his observations were within normal limits, with no documented fevers or tachycardia. Physical exam was unremarkable. Serial electrocardiogram (ECG, Figure [1](#F1){ref-type="fig"}) revealed prominent ST elevation (\> 2 mm in leads V2-V6, \> 1 mm in II/aVF), as well as ST depression in aVR. Investigations revealed a white cell count (WCC) of 7.3 × 10^9^/L, C-reactive protein (CRP) of 84 mg/L, as well as a Troponin I (Abbott Architect) of 14,757 ng/L and a creatinine kinase of 594 units/L. Other blood tests such as electrolytes, creatinine and liver function tests were unremarkable.

![Electrocardiography from admission, showing diffuse ST elevation and mild ST depression in automatic voltage regulator.](WJC-12-67-g001){#F1}

Imaging examinations
--------------------

Chest X-ray showed mild cardiac enlargement, without signs of pulmonary oedema or pneumonia. Faeces microscopy and culture, along with blood cultures were taken, and the patient was admitted without specific antimicrobial treatment. An echocardiogram conducted the next day showed a trivial amount of pericardial fluid. The was no clinical or echocardiographic evidence of tamponade, ventricular dysfunction, or thrombus formation.

During Day 5, we were notified of a *Salmonella* species from the faecal culture organised by the GP. Treatment was commenced with 1 g of ceftriaxone daily. Later that night there was an associated, asymptomatic rise in the Troponin I from the previous nadir of 8,915 to 15,114 ng/L. Ceftriaxone was increased to 2 g daily, and the Infectious Diseases Unit were consulted. At this stage the repeat faecal culture also identified *Salmonella* species, with negative blood cultures at 48 h. Joint decision at this stage was made to change to azithromycin 500 mg daily for 5 d and to not initiate non-steroidal therapy, given that the initial presenting symptoms had fully resolved. There had been no clinical events of arterial or venous thrombus, combined with no significant echocardiography changes, therefore no anticoagulation was prescribed. After a further period of observation over 24 h, during which the troponin decreased to 11,327 ng/L, the patient was discharged home.

Post discharge, at Day 7, the initial presenting blood culture was positive for gram negative bacilli in one aerobic bottle, out of two sets, also identified as *Salmonella typhimurium*, however by this stage the patient was convalescing well at home.

FINAL DIAGNOSIS
===============

Myopericarditis in the setting of *Salmonella typhimurium* gastroenteritis and bacteraemia.

TREATMENT
=========

Two days of ceftriaxone 2 g IV daily followed by azithromycin 500 mg orally daily for 5 days.

OUTCOME AND FOLLOW-UP
=====================

Clinical and biochemical resolution of myopericarditis and *Salmonella typhimurium* infection. Patient well with no further complaints at routine one-month follow-up.

DISCUSSION
==========

The presentation of NTS myopericarditis can be varied, but generally is divided into two categories, the symptoms of myopericarditis, and the diarrhoeal syndrome. Although the manifestations of myopericarditis are commonly a spectrum between myocarditis and pericarditis, there is often a predominance of on\[[@B2]\]. Myocarditis typically presents with chest pain, often of a varied nature, and can be impossible to differentiate on history from ischaemic chest pain. Otherwise heart failure symptoms, flu-like symptoms, fatigue, palpitations, syncope, or even sudden cardiac death may be the presenting symptom\[[@B5]\]. Pericarditis is associated with a pleuritic chest pain, often relieved by learning forward, as well as fatigue, palpitations, dyspnoea, and potentially tamponade\[[@B5]\]. The classic exam finding is the pericardial friction rub, often described as a scratching sound best heard over the left sternal edge. Purulent pericarditis, a rare subset in the antibiotic era, should nevertheless be considered given its high morbidity and mortality. Presenting symptoms may include signs of pericarditis, especially if associated with sepsis or bacteraemia, with *Salmonella aureus* being the most commonly identified organism.

Investigations of relevance in myopericarditis include ECG, echocardiography, laboratory blood tests, biopsy, coronary angiography and cardiac magnetic resonance imaging. ECG changes are varied\[[@B6]\], but typically involve diffuse ST elevation and PR depression, progressing to normalization of segments with subsequent T-wave inversion. However, given this can also manifest as focal ST elevation, combined with the fact that the pain can be ischaemic in nature, differentiation from acute coronary syndromes (ACS) is often required. This is most frequently done with interventional angiography, or more recently computed tomography coronary angiography. Aside from raised troponin, inflammatory markers such as WCC and CRP are often raised, however this has not been shown to help differentiate NTS as a cause\[[@B7]\]. Echocardiography is another critical area of investigation, as this can help identify ventricular dysfunction, valvular incompetence and thrombus in myocarditis\[[@B8]\], as well as the extent of pericardial involvement, ranging from completely normal to cardiac tamponade in pericarditis\[[@B9]\]. Cardiac magnetic resonance imaging is another investigation that can be potentially used, as it can accurately assess inflammation in either the pericardium or myocardium, as well as help differentiate between ACS\[[@B10]\]. Definitive diagnosis of myocarditis requires endocardial biopsy, however indication revolves around whether a biopsy result would change patient management, and thus is rarely conducted in those with normal or only mildly impaired ventricular function\[[@B11]\]. Biopsy is most frequently performed in cases of fulminant heart failure, heart failure with rhythm disturbance, or when there is peripheral eosinophilia, suggestive of eosinophilic myocarditis.

The most recognised infection from *Salmonella* is typhoid fever, also known as enteric fever, caused by *Salmonella enterica* serotype Typhi (formerly *Salmonella typhi*), as well as *Salmonella paratyphi* (*Salmonella enterica* serotype *paratyphi*). Due to a nomenclature change, within Salmonella there are now two species; *bongori* and *enteric*\[[@B12]\]. *Salmonella enterica*, which causes the majority of infections, contains 6 subspecies, of which the most clinically relevant is *Salmonella enterica* subspecies *enterica*. These are then further divided into serovars, with the most common including: *Salmonella choleraesuis*, *Salmonella enteritidis*, and *Salmonella typhimurium*. These organisms make up the group known as NTS.

NTS often manifests within 72 h of exposure to the offending pathogen and is usually associated with faecal-oral contamination. The most common presenting symptoms by far is gastroenteritis\[[@B13]\], associated with watery, non-bloody diarrhoea, abdominal cramps, nausea and vomiting, as well as fever.

In our review of the literature (Table [1](#T1){ref-type="table"}), we found 42 reported cases of NTS (Table [2](#T2){ref-type="table"}), with 9 myocarditis, 6 myopericarditis and 27 cases of pericarditis. Overall, we found that *Salmonella enteritidis* was the most common organism, representing 18 (42.9%) of all reported cases, with *Salmonella typhimurium* at 31.7%. Males consisted 71.4% of the cases, and the average age of patients was 48.3 years. In the case studies that we have identified, the overall mortality rate was 31%, and up to 77.8% in myocarditis cases, compared to 14.8% in pericarditis. Tamponade was the most commonly reported complication, especially in pericarditis, at 54.3%, whilst ventricular rupture was the most commonly reported complication of myocarditis. However, this is limited by both reporting and publication bias, and by the fact that most deaths and myocarditis cases occurred earlier in time, prior to modern diagnostic techniques and treatment.

###### 

Non-typhoidal salmonella pericarditis and myocarditis

  **Author**                                 **Relevant medical history**                                    **Age and sex**   **Cardiac manifestation**   **Organism**                **Complications**            **Outcome**
  ------------------------------------------ --------------------------------------------------------------- ----------------- --------------------------- --------------------------- ---------------------------- -------------
  Bengtsson et al\[[@B20]\], 1955            NA                                                              50F               Myocarditis                 *Salmonella typhimurium*    NA                           Deceased
  Bengtsson et al\[[@B20]\], 1955            NA                                                              51M               Myocarditis                 *Salmonella typhimurium*    NA                           Deceased
  Sanders et al\[[@B21]\], 1964              NA                                                              62F               Myocarditis                 *Salmonella choleraesuis*   Ventricular Rupture          Deceased
  Shilkin et al\[[@B22]\], 1969              SLE                                                             61M               Myopericarditis             *Salmonella typhimurium*    Endocarditis                 Deceased
  Schatz et al\[[@B23]\], 1973               NA                                                              62M               Myopericarditis             *Salmonella typhimurium*    Tamponade                    Deceased
  Webster et al\[[@B24]\], 1977              NA                                                              19F               Myopericarditis             *Salmonella agona*          NA                           Survived
  Simonsen et al\[[@B25]\], 1980             NA                                                              24M               Myocarditis                 *Salmonella typhimurium*    NA                           Deceased
  Götz et al\[[@B26]\], 1983                 NA                                                              53M               Myocarditis                 *Salmonella typhimurium*    NA                           Deceased
  Martínez-Martínez et al\[[@B27]\], 1989    NA                                                              60M               Myocarditis                 *Salmonella enteritidis*    Mycotic aneurysms of aorta   Deceased
  Burt et al\[[@B28]\], 1990                 NA                                                              29M               Myocarditis                 *Salmonella Heidelberg*     VF                           Deceased
  Dunbabin et al\[[@B29]\], 1990             Chemotherapy                                                    52F               Pericarditis                *Salmonella Dublin*         Tamponade                    Deceased
  Doig et al\[[@B30]\], 1991                 NA                                                              36F               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Clesham et al\[[@B31]\], 1993              NA                                                              45M               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Li et al\[[@B32]\], 1993                   NA                                                              22F               Pericarditis                *Salmonella enteritidis*    NA                           Survived
  Yang et al\[[@B33]\], 1995                 NA                                                              54F               Pericarditis                *Salmonella typhimurium*    NA                           Survived
  Victor et al\[[@B34]\], 1997               NA                                                              71M               Pericarditis                *Salmonella enteritidis*    NA                           Survived
  Kiuchi et al\[[@B35]\], 1998               ITP (prednisolone)                                              39M               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Badawi et al\[[@B36]\], 2002               NA                                                              48M               Pericarditis                *Salmonella typhimurium*    NA                           Survived
  Pace et al\[[@B37]\], 2002                 NA                                                              65M               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Salavert et al\[[@B38]\], 2002             NA                                                              61M               Pericarditis                *Salmonella arizonae*       Tamponade                    Survived
  Candel et al\[[@B39]\], 2003               HIV                                                             37M               Pericarditis                *Salmonella Derby*          NA                           Survived
  Yoshioka et al\[[@B40]\], 2003             NA                                                              40M               Pericarditis                *Salmonella enteritidis*    NA                           Survived
  Arruvito et al\[[@B41]\], 2004             Arthritis (steroids)                                            75M               Pericarditis                *Salmonella enterica*       Tamponade                    Deceased
  Can et al\[[@B42]\], 2004                  NA                                                              42M               Pericarditis                *Salmonella typhimurium*    NA                           Deceased
  Fernández Guerrero et al\[[@B43]\], 2004   SLE (prednisolone and azathioprine)                             23F               Pericarditis                *Salmonella typhimurium*    Tamponade                    Survived
  Fernández Guerrero et al\[[@B43]\], 2004   NA                                                              66M               Myopericarditis             *Salmonella enteritidis*    NA                           Survived
  Hoag et al\[[@B44]\], 2005                 HIV                                                             47F               Pericarditis                *Salmonella arizonae*       Tamponade                    Survived
  Górecki et al\[[@B45]\], 2008              RA (steroids) ESRF (on HDx)                                     64M               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Sahu et al\[[@B46]\], 2008                 Hodgkin's lymphoma                                              23M               Pericarditis                *Salmonella typhimurium*    NA                           Survived
  Takamiya et al\[[@B47]\], 2008             CD4/CD8 depression (ratio = 0.81)                               65M               Pericarditis                *Salmonella enteritidis*    NA                           Survived
  Hibbert et al\[[@B48]\], 2010              NA                                                              25M               Myopericarditis             *Salmonella enteritidis*    NA                           Survived
  Tseng et al\[[@B49]\], 2010                ESRF                                                            66M               Pericarditis                *Salmonella enterica*       Tamponade                    Survived
  Tseng et al\[[@B49]\], 2010                ESRF                                                            82M               Pericarditis                *Salmonella enteritidis*    Tamponade                    Deceased
  Ortiz et al\[[@B50]\], 2014                SLE (prednisolone)                                              62M               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Chand et al\[[@B51]\], 2015                NA                                                              67M               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Zaman et al\[[@B52]\], 2015                NA                                                              67M               Myopericarditis             *Salmonella enteritidis*    Tamponade                    Survived
  Dawar et al\[[@B53]\], 2017                NA                                                              46F               Pericarditis                *Salmonella typhimurium*    NA                           Survived
  Kuo et al\[[@B54]\], 2017                  Adult onset Still's disease (methylprednisolone/prednisolone)   30F               Pericarditis                *Salmonella enteritidis*    Tamponade                    Survived
  Suzuki et al\[[@B55]\], 2017               NA                                                              31M               Pericarditis                *Salmonella arizonae*       Tamponade                    Survived
  Ezad et al\[[@B56]\], 2018                 NA                                                              29F               Myocarditis                 *Salmonella typhimurium*    NA                           Survived
  Sundbom et al\[[@B57]\], 2018              NA                                                              22M               Myocarditis                 *Salmonella enteritidis*    NA                           Survived
  Saddler et al\[[@B58]\], 2019              Crohn's disease (Infliximab)                                    57M               Pericarditis                *Salmonella enterica*       Tamponade                    Survived

NA: Not applicable; SLE: Systemic lupus erythematosus; ESRF: End-stage renal failure; HIV: Human immunodeficiency virus; RA: Rheumatoid arthritis; ITP: Idiopathic thrombocytopenic purpura; M: Male; F: Female.

###### 

Summary of non-typhoidal salmonella ca

  **Cardiac Manifestation (Cases)**   **Organisms (Number of cases)**   **Mortality**
  ----------------------------------- --------------------------------- ---------------
  Myocarditis (9)                     *Salmonella typhimurium* (5)      77.8% (7/9)
  *Salmonella enteritidis* (2)                                          
  *Salmonella choleraesuis* (1)                                         
  *Salmonella Heidelberg* (1)                                           
  Myopericarditis (6)                 *Salmonella enteritidis* (3)      33.3% (2/6)
  *Salmonella typhimurium* (2)                                          
  *Salmonella agona* (1)                                                
  Pericarditis (27)                   *Salmonella enteritidis* (13)     14.8% (4/27)
  *Salmonella typhimurium* (6)                                          
  *Salmonella arizonae* (3)                                             
  *Salmonella enterica* (3)                                             
  *Salmonella Derby* (1)                                                
  *Salmonella Dublin* (1)                                               
  Total (42)                          *Salmonella enteritidis* (18)     31% (13/42)
  *Salmonella typhimurium* (13)                                         
  *Salmonella arizonae* (3)                                             
  *Salmonella enterica* (3)                                             
  *Salmonella agona* (1)                                                
  *Salmonella choleraesuis* (1)                                         
  *Salmonella Derby* (1)                                                
  *Salmonella Dublin* (1)                                               
  *Salmonella Heidelberg* (1)                                           

The mainstay of therapy in treating the inflammation and pain associated with myopericarditis is non-steroidal anti-inflammatory drugs (NSAIDs)\[[@B3]\]. However when there is a predominant myocarditic component, NSAIDs are often reconsidered, as animal models show increased inflammation and mortality in viral myocarditis\[[@B14]\]. Corticosteroids are also potentially used, but should only be considered in cases of ongoing uncontrolled inflammation, as there is minimal data to recommend its routine use, and there is association with recurrent myocarditis\[[@B15]\]. Anticoagulation can be considered in specific patients, similar to the indications in non-ischaemic dilated cardiomyopathy\[[@B16]\]. These would be if there were new onset AF, clinical or radiographical evidence of arterial or venous thromboembolism, thrombus formation on the echogardiogram, or significant ventricular dysfunction. If treatment was indicated, evidence currently leans towards anticoagulation with warfarin or a Direct Oral Anti-Coagulant, as opposed to single-agent treatment with an antiplatelet\[[@B17]\]. If there are concurrent symptoms of heart failure, routine heart failure treatment should be initiated, including diuretics, angiotensin converting enzyme inhibition, and extended release beta blocker treatment. Invasive treatment is often limited to coronary angiography when differentiating from ACS, as well as pericardiocentesis in the setting of large pericardial effusions with features suggestive of developing or frank cardiac tamponade.

Lastly, it is also important to treat the underlying *Salmonella* infection, however guidelines vary secondary to local antimicrobial susceptibility patterns. After clinical rehydration, current Australian guidelines\[[@B18]\], recommend treatment with intravenous therapy initially, such as ceftriaxone (2 g IV daily), or ciprofloxacin (400 mg twice-daily), before an oral tail of ciprofloxacin/azithromycin, determined by the severity of the infection.

At this stage, there is very limited high-quality data on long-term prognosis and complications in patients diagnosed with myopericarditis\[[@B3]\]. Nevertheless, it appears that survival rates in idiopathic and infectious myocarditis are overall quite favourable, especially the predominant pericarditis subtype\[[@B19]\]. The main complications are the development or non-resolution of heart failure, cardiomyopathy, arrhythmias, and sudden cardiac death, especially if there is significant myocardial scarring. Routine follow up in the acute phase with echocardiography is recommended, especially if there are clinical or radiological signs of heart failure.

CONCLUSION
==========

The presentation of NTS myopericarditis is varied, however it revolves around two main areas, the symptoms of myocarditis and pericarditis, as well as the infectious symptoms of diarrhoea accompanying Salmonella infection. Definitive diagnosis with biopsy is rarely undertaken, as this is usually a clinical diagnosis from the clinical history and examination, ECG, troponin and echocardiogram, as well as a stool culture for the NTS. There is a lack of consensus regarding the treatment of myopericarditis, however there are well established antibiotic guidelines for NTS. Although NTS is a rare cause of myopericarditis, given the severity of potential sequelae, remains a worthwhile consideration when patients present with symptoms of both infectious diarrhoea and myopericarditis.
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